Identification of deficient mitochondrial signaling in apoptosis resistant leukemia cells by flow cytometric analysis of intracellular cytochrome c, caspase-3 and apoptosis.
Deficient activation of apoptosis signaling pathways may be responsible for treatment failure of malignant diseases. In primary leukemia samples the detection of deficient mitochondrial apoptosis signaling would enable identification of chemo-resistant cells. To investigate the key events of apoptosis at the mitochondrial level, we developed a flow cytometric method for simultaneous detection of mitochondrial cytochrome c release and caspase-3 processing using conformation sensitive monoclonal antibodies. This method proved to identify deficient mitochondrial apoptosis signaling in leukemia cells overexpressing Bcl-2 by a pattern of apoptosis resistance, deficient cytochrome c reduction and partial processing of caspase-3. In primary leukemia cells, reduction of cytochrome c and caspase-3 activation was induced by treatment with anticancer drugs in vitro. In leukemia cells of a patient with resistant disease, a pattern of deficient apoptosis signaling as in Bcl-2 transfected cells was observed, suggesting that deficient mitochondrial signaling contributed to the clinical phenotype of drug resistance in this patient. Flow cytometric analysis of mitochondrial apoptosis signaling may provide a useful tool for the prediction of drug resistance and treatment failure in primary leukemia.
Stahnke
K
K
University Children's Hospital, Ulm. Germany.
Mohr
A
A
Liu
J
J
Meyer
L H
LH
Karawajew
L
L
Debatin
K-M
KM
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D017209:Apoptosis; D015153:Blotting, Western; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism*; D002463:Cell Membrane Permeability / Q000187:drug effects; D003520:Cyclophosphamide / Q000494:pharmacology; D045304:Cytochromes c / Q000276:immunology / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000494:pharmacology; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D019169:Jurkat Cells; D007938:Leukemia / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000378:metabolism; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000378:metabolism; D008856:Microscopy, Fluorescence; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000502:physiology; D015398:Signal Transduction; D014162:Transfection; D019014:fas Receptor / Q000276:immunology
D000911:Antibodies, Monoclonal; D019253:Proto-Oncogene Proteins c-bcl-2; D019014:fas Receptor; D005047:Etoposide; D003520:Cyclophosphamide; D045304:Cytochromes c; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases